1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Insulin Resistance-Pipeline Insights, 2017

Insulin Resistance-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Insulin Resistance-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Insulin Resistance. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Insulin Resistance. DelveInsight’s Report also assesses the Insulin Resistance therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Insulin Resistance
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Insulin Resistance pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Insulin Resistance and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Insulin Resistance-Pipeline Insights, 2017
Illustrative

- Insulin Resistance Overview
- Insulin Resistance Pipeline Therapeutics
- Insulin Resistance Therapeutics under Development by Companies
- Insulin Resistance Filed and Phase III Products
- Comparative Analysis
- Insulin Resistance Phase II Products
- Comparative Analysis
- Insulin Resistance Phase I and IND Filed Products
- Comparative Analysis
- Insulin Resistance Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Insulin Resistance - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Insulin Resistance - Discontinued Products
- Insulin Resistance - Dormant Products
- Companies Involved in Therapeutics Development for Insulin Resistance
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Insulin Resistance, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Insulin Resistance Assessment by Monotherapy Products
- Insulin Resistance Assessment by Combination Products
- Insulin Resistance Assessment by Route of Administration
- Insulin Resistance Assessment by Stage and Route of Administration
- Insulin Resistance Assessment by Molecule Type
- Insulin Resistance Assessment by Stage and Molecule Type
- Insulin Resistance Therapeutics - Discontinued Products
- Insulin Resistance Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Insulin Resistance, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Insulin Resistance Assessment by Monotherapy Products
- Insulin Resistance Assessment by Combination Products
- Insulin Resistance Assessment by Route of Administration
- Insulin Resistance Assessment by Stage and Route of Administration
- Insulin Resistance Assessment by Molecule Type
- Insulin Resistance Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...

US Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedView

US Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedView

  • $ 3995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description Diabetes mellitus is a multifaceted disease that yields various approaches in terms of diagnosis, treatment and drug delivery. Products for maintenance and treatment of diabetes can be of high ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Sweden

  • February 2017
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Insulin Market and Diabetes Statistics in the US

  • February 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • February 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Therapy Market

9 days ago

Related Market Segments :

Insulin

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.